|
| 23 January 2019 |
ALLIANCE PHARMA PLC
("Alliance" or the "Company")
Director Shareholding
Alliance Pharma plc (AIM: APH), the speciality pharmaceutical company, was notified on 22 January 2019 that on 22 January 2019 Richard Jones, a Non-Executive Director of the Company, purchased 15,000 ordinary shares of 1.0p each in the Company ("Ordinary Shares") at a price of 65.28 pence per share.
Following this transaction, Mr Jones' total beneficial interest in the Company is 15,000 Ordinary Shares, representing less than 0.01% of the Company's issued share capital.
The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.
| 1 | Details of the person discharging managerial responsibilities/person closely associated | ||
| a) | Name | Richard Jones | |
| 2 | Reason for the notification | ||
| a) | Position/status | Non-Executive Director | |
| b) | Initial notification /Amendment | Initial Notification | |
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||
| a) | Name | Alliance Pharma Plc | |
| b) | Legal Entity Identifier | 213800RYIWZA4Q5WPZ13
| |
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
| a) | Description of the financial instrument, type of instrument
Identification code | Ordinary shares of 1 pence each
GB0031030819
| |
| b) | Nature of the transaction | Purchase of shares | |
| c) | Currency | GBP
| |
| d) | Price(s) and volume(s) | Price(s) | Volume(s) |
| 65.28p | 15,000 | ||
|
| |||
| e) | Aggregated information - Aggregated volume - Price - Aggregated total |
n/a
| |
| f) | Date of the transaction | 22 January 2019 | |
| g) | Place of the transaction | London Stock Exchange, AIM | |
For further information:
| Alliance Pharma plc | + 44 (0)1249 466966 |
| Peter Butterfield, Chief Executive Officer |
|
| Andrew Franklin, Chief Financial Officer |
|
| www.alliancepharma.co.uk |
|
| Buchanan | + 44 (0)20 7466 5000 |
| Mark Court / Sophie Wills / Hannah Ratcliff |
|
|
|
|
| Numis Securities Limited | + 44 (0)20 7260 1000 |
| Nominated Adviser: Michael Meade / Freddie Barnfield |
|
| Corporate Broking: James Black |
|
| Investec Bank plc | + 44 (0)20 7597 5970 |
| Corporate Finance: Daniel Adams / Ed Thomas |
|
| Corporate Broking: Patrick Robb / David Herring |
|
About Alliance
Alliance Pharma plc (AIM: APH) is an international healthcare group, headquartered in the UK with affiliate offices in Europe, the Far East and the US and wide international reach through an extensive network of distributors, generating sales in more than 100 countries.
We currently own or license the rights to more than 90 pharmaceutical and consumer healthcare products, which are managed on a portfolio basis according to their growth potential. Promotional investment is focussed on a small number of brands with significant international or multi-territory reach. The remainder of the portfolio comprises products which are sold in a limited number of local markets and require little or no promotional investment.
Our tried and tested 'Buy and Build' strategy, allows us to benefit both from organic growth opportunities and from enhancing our growth rate through carefully selected acquisitions.
For more information on Alliance, please visit our website: www.alliancepharmaceuticals.com